Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy
- PMID: 16246056
- DOI: 10.1042/BST20051106
Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy
Abstract
There is strong evidence for the involvement of alpha-synuclein in the pathologies of several neurodegenerative disorders, including PD (Parkinson's disease). Development of disease appears to be linked to processes that increase the rate at which alpha-synuclein forms aggregates. These processes include increased protein concentration (via either increased rate of synthesis or decreased rate of degradation), and altered forms of alpha-synuclein (such as truncations, missense mutations, or chemical modifications by oxidative reactions). Aggregated forms of the protein are toxic to cells and one therapeutic strategy would be to reduce the rate at which aggregation occurs. To this end we have designed several peptides that reduce alpha-synuclein aggregation. A cell-permeable version of one such peptide was able to inhibit the DNA damage induced by Fe(II) in neuronal cells transfected with alpha-synuclein (A53T), a familial PD-associated mutation.
Similar articles
-
Controlling the mass action of alpha-synuclein in Parkinson's disease.J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Epub 2008 Sep 2. J Neurochem. 2008. PMID: 18691382 Review.
-
Interactions between metals and alpha-synuclein--function or artefact?FEBS J. 2007 Aug;274(15):3766-74. doi: 10.1111/j.1742-4658.2007.05917.x. Epub 2007 Jul 6. FEBS J. 2007. PMID: 17617226 Review.
-
A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.Nat Neurosci. 2008 Mar;11(3):301-8. doi: 10.1038/nn2058. Epub 2008 Feb 24. Nat Neurosci. 2008. PMID: 18297066
-
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.FASEB J. 2004 Aug;18(11):1315-7. doi: 10.1096/fj.03-1346fje. Epub 2004 Jun 4. FASEB J. 2004. PMID: 15180968
-
alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.Neurobiol Dis. 2007 Jun;26(3):521-31. doi: 10.1016/j.nbd.2007.01.014. Epub 2007 Feb 16. Neurobiol Dis. 2007. PMID: 17408955
Cited by
-
T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls.Front Neurosci. 2020 Aug 27;14:874. doi: 10.3389/fnins.2020.00874. eCollection 2020. Front Neurosci. 2020. PMID: 32982670 Free PMC article.
-
A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.Mol Divers. 2019 May;23(2):509-526. doi: 10.1007/s11030-018-9878-4. Epub 2018 Oct 6. Mol Divers. 2019. PMID: 30293116 Review.
-
Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.ACS Chem Neurosci. 2014 Aug 20;5(8):700-17. doi: 10.1021/cn500084x. Epub 2014 Jul 9. ACS Chem Neurosci. 2014. PMID: 24960209 Free PMC article.
-
Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Clin Geriatr Med. 2010 Feb;26(1):125-47. doi: 10.1016/j.cger.2009.12.003. Clin Geriatr Med. 2010. PMID: 20176298 Free PMC article. Review.
-
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9. Mol Neurodegener. 2016. PMID: 26782965 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
